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The alkenylbenzene estragole (systematic name, 1-allyl-4-methoxybenzene) is a natural component of essential oils 
from various spices and herbs, including fennel, and it is used as a food and beverage fl avouring agent. Estragole has 
been reported to be hepatocarcinogenic at high doses in rodents. However, in a previous in vitro study, we found that 
estragole did not exhibit cytotoxic effects after 4 hours of exposure, nor did it induce DNA damage or apoptosis in 
human HepG2 hepatoblastoma cells. As fennel tea is widely used for symptomatic treatment of spasmodic 
gastrointestinal conditions in infants, we aimed at further assessing its safety in a different experimental setting. We 
thus searched for possible cytogenetic effects and interference with cell-cycle progression in the same human 
hepatoblastoma cell line. Estragole did not show any clastogenic/aneugenic activities in the cytokinesis-block 
micronucleus assay, and no effects on cell-cycle checkpoints were observed.
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The alkenylbenzene estragole (systematic name: 1-allyl-4-methoxybenzene) is a natural 
constituent of essential oils from a variety of spices and herbs such as nutmeg, basil, anise, 
mace, tarragon, fennel, and pimento. Extracts of these herbs have been used as fl avouring 
agents mostly in baked goods, non-alcoholic beverages, and candy (SMITH et al., 2002). 
Estragole intake from all sources ranges from 0.01 mg/kg bw (SMITH et al., 2002) to 0.07 mg/kg 
bw (EC, 2001), mostly originating from fennel infusions, widely used as an antispasmodic 
remedy. Infants represent the widest consumer group of fennel tea, to treat symptoms of 
spasmodic gastrointestinal illnesses (VAN DEN BERG et al., 2014). Estragole is, however, 
hepatocarcinogenic at high doses in rodents because of its bioactivation by cytochromes of 
the P450 family. In fact, estragole is quickly absorbed by the gastrointestinal tract, and is 
thereby transported to the liver, where it is catabolised along two distinct metabolic pathways 
(PUNT et al., 2010; PAINI et al., 2012; VILLARINI et al., 2014).
Because of the presumed genotoxicity and rodent carcinogenicity of some of its 
metabolites, the use of estragole as a pure substance in foodstuffs has been prohibited within 
the European Union since September 2008 (EC, 2008). In line with the recommendations for 
any supposed genotoxic/carcinogenic compound, the European Food Safety Authority 
(EFSA) has recently indicated that, as to the amount estragole to be allowed in herbal 
preparations, including fennel-based teas, a Margin of Exposure (MoE) approach (EFSA, 
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2005) should be applied in evaluating any potential risks in humans and the priority for risk 
management actions (EFSA, 2009a). The MoE is defi ned as the ratio between exposure 
levels causing malignant tumours in experimental animals (e.g. the BMDL10 value, the 
lower bound of the confi dence interval of the benchmark dose that gives a 10% extra incidence 
of cancer) and the estimated daily intake in humans.
Based on experimental exposure data of estragole resulting from the consumption of 
homemade fennel tea and on BMDL10 values derived from the incidence of malignant liver 
tumours in female CD-1 mice exposed to estragole, different MoE values have been calculated 
(MILLER et al., 1983; EFSA, 2009b; RAFFO et al., 2011; VAN DEN BERG et al., 2014). RAFFO and 
co-workers (2011) reported a MoE value ranging from 870 to 3,210, with these values being 
lower than 10 000 and thus indicating a potential risk for human health and a priority for risk 
management actions. In contrast, VAN DEN BERG and co-workers (2014) reported MoE values 
that were generally above the default value of 10 000 (i.e. 25 samples out of 34). Such 
discrepancies in MoE values are likely the consequence of different procedures in estimating 
the daily intake levels in the same exposure scenario. In fact, different methods for exposure 
evaluation (e.g., theoretical vs. experimental) and differences in extraction effi ciency of 
estragole from a vegetal matrix are major sources of uncertainty in safety assessment. 
Moreover, criticisms have been raised regarding the extrapolation of carcinogenicity data 
from animal models to humans. In this context, one important issue to consider is whether the 
reported genotoxic and/or carcinogenic effects are a high-dose-related phenomenon; in this 
case, the effect would not occur under the conditions typical of human exposure. It might also 
be important to consider how the compound is metabolized, as the process may be different 
between animals and humans, and this may thus result in marked differences in toxicity.
In a previous study (VILLARINI et al., 2014), we have assessed the cytotoxic, genotoxic 
(primary DNA damage evaluated by the ‘comet’ assay), and apoptotic activities of estragole 
in the human hepatoblastoma cell line HepG2. Data reported in the above-mentioned paper 
demonstrated that estragole, under the adopted experimental conditions, was not cytotoxic, 
and it failed to induce DNA damage or apoptosis. However, a limitation of the comet assay 
is that aneugenic effects and indirect DNA fi delity interaction liabilities – including effects 
on cell-cycle checkpoints – are not detectable (WITTE et al., 2007).
In this work, we have addressed these issues in human liver (HepG2) cells treated for 24 
hours with three concentrations of estragole. Clastogenic and aneugenic events were 
evaluated by the cytokinesis-block micronucleus (CBMN) assay; cell-cycle analysis was 
conducted by DNA content quantifi cation (fl uorescence microscopy and image analysis) and 
hence, measurements of cell-cycle stage (e.g. G1/G0, S, or G2/M phase). The HepG2 
hepatoblastoma-derived cell line was originally established in 1979 from the liver tissue of a 
15-year-old Caucasian boy (ADEN et al., 1979), and listed on the ATCC (American Type 
Culture Collection, Rockville, MD, USA) repository as a human cell line (HB 8065). HepG2 
cells retain many metabolic characteristics of hepatocytes; in particular, they have been 
reported to express cytochrome P450 (CYP) 1A2-dependent enzymes (involved in phase I 
reactions) and sulfotransferase (SULT) 1A1 (phase II reactions) responsible for estragole 
metabolism (WESTERINK & SCHOONEN, 2007).
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1. Materials and methods
1.1. Chemicals and reagents
Estragole (IUPAC name: 1-methoxy-4-prop-2-enylbenzene; CAS No: 140-67-0) was 
purchased from Sigma–Aldrich Italia Srl, Milan, Italy, with purity certifi ed to be ≥98.5%. All 
reagents were analytical grade unless otherwise stated.
1.2. Cell cultures and exposure
HepG2 cells (ATCC HB 8065) were obtained from Istituto Zooprofi lattico Sperimentale 
della Lombardia e dell’Emilia Romagna ‘Bruno Ubertini’ (Brescia, Italy). Cells were grown 
as monolayer cultures and sub-cultured for in vitro testing, as described in detail elsewhere 
(VILLARINI et al., 2014; LOMBARDI et al., 2015).
1.3. Lactate dehydrogenase (LDH) assay
The concentrations of estragole tested in the lactate dehydrogenase (LDH) assay were: 84.55, 
42.28, 21.14, 10.57, 5.28, 2.64, 1.32, 0.66, and 0.33 μg ml–1. These concentrations were chosen 
following the test method protocol for solubility determination (NICEATM/ICCVAM, 2006). 
LDH activity was measured in culture media as an index of cytotoxicity using the Takara’s 
LDH Cytotoxicity Detection Kit (Takara Bio Inc. Otsu, Japan), and absorbance was recorded 
using a Tecan Sunrise microplate reader (Tecan Italia Srl, Milan, Italy). Experiments had been 
done in triplicate. Cytotoxicity was expressed as percent LDH activity present in supernatants 
of estragole-treated cells relative to that in cells incubated with 1% Triton X-100.
1.4. Cytokinesis-block micronucleus (CBMN) test
Estragole was tested in the cytokinesis-block micronucleus (CBMN) test using the three 
highest non-cytotoxic concentrations defi ned in the LDH assay. The CBMN test was 
performed according to the original method (FENECH, 2000) with minor modifi cations. Steps 
of the CBMN test are as described in detail elsewhere (DOMINICI et al., 2010; VILLARINI et al., 
2011). For each experimental group, 1000 BNC (binucleated cells) were analysed, and the 
MN frequency was calculated based on established criteria (FENECH, 2000). Furthermore, to 
investigate the impact of the tested compound on cell proliferation, the nuclear division index 
(NDI) was calculated for each experimental point (EASTMOND & TUCKER, 1989). The results 
for MN and NDI were expressed as the mean±standard deviation of triplicate determinations 
from independent experiments.
1.5. Analysis of cell-cycle
As for the CBMN test, cell-cycle analysis was carried out using the three highest non-
cytotoxic concentrations of estragole defi ned by the LDH assay. Cells were plated in six-well 
plates at 106 cells per well and cultured for 24 hours. Cell cultures were then exposed to 
estragole for 24 hours. At the end of the treatment, cells were harvested, fi xed with 70% 
ethanol, and maintained at 0–4 °C for 24 hours. After centrifugation, cell pellets were washed 
with PBS and treated for 5 min at 37 °C with 0.5 ml of PBS containing 1 μg ml–1 DAPI and 
0.1% triton X-100. After staining, DAPI fl uorescence was quantifi ed by fl uorescence 
microscopy with the automated cytometer NucleoCounter® NC-3000™ (ChemoMetec A/S, 
Allerød, Denmark).
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1.6. Statistical analysis
Data were analysed using the statistical package SPSS (SPSS Inc., IL, USA). Variables were 
tested for normality with the Kolmogorov–Smirnov test. Statistical signifi cance of differences 
was evaluated by one-way analysis of variance (ANOVA), followed by Dunnet post hoc 
analysis. To check for the occurrence of concentration-dependent responses, Pearson’s 
correlation coeffi cients (r) were calculated. The chosen level of signifi cance was 0.05.
2. Results and discussion
2.1. Cytotoxicity
Only exposure to the highest concentration of estragole (84.55 μg ml–1) caused clearly 
cytotoxic effects (percent cytotoxicity: 20.35±3.60) and, therefore, this concentration was 
not suitable for use in the subsequent experiments, as genotoxicity and cell-cycle tests need 
viability equal or superior to 80% to be performed. All the other concentrations tested resulted 
to be not cytotoxic (data not shown).
2.2. Cytokinesis-block micronucleus test
The number of micronuclei (MN) per 1000 BNC was assessed as a measure of chromosomal 
abnormalities via the CBMN test in HepG2 cells exposed to a range of estragole concentrations. 
Based on cytotoxicity data, the CBMN test was carried out by testing 42.28, 21.14, and 10.57 
μg ml–1 estragole. A minor increase in MN (number of micronuclei) was observed when cells 
were exposed to the highest concentration tested relative to MN frequency in negative 
controls (Table 1), however, the increase did not reach the level of signifi cance. Additionally, 
NDI – measured to verify any possible cytostatic effects of estragole – did not decrease 
signifi cantly when compared to control cells (Table 1).
Table 1. Induction of micronuclei in human HepG2 cells by estragole
Estragole MN/1000 BNC NDI
42.28 μg ml–1 7.00±1.26 1.75±0.06
21.14 μg ml–1 6.67±0.73 1.68±0.09
10.57 μg ml–1 5.67±0.60 1.74±0.08
Negative control 4.83±0.44 1.72±0.04
Positive control 11.67±1.09 1.75±0.05
MN: micronuclei; BNC: binucleated cells; NDI: nuclear division index
2.3. Analysis of cell-cycle
The same concentrations as those used in the CBMN test were also used for cell-cycle 
analysis. As shown in Figure 1, treatment with estragole resulted in changes in cell-cycle 
distribution of HepG2 cells that were characterized by a minor accumulation of cells in the 
G0/G1 phase in a concentration-dependent manner (r=0.506; P=0.046). Simultaneously, a 
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non-signifi cant reduction in number of cells in the G2/M phase after 24 hours exposure to 
estragole was detected.
Fig. 1. Cell-cycle distribution of human hepatoma HepG2 cells treated for 24 hours with different concentrations 
of estragole
: G2/M; : S; : G0/G1; G: gap phase; S: synthesis; M: mitosis
GORI and co-workers (2012) have suggested that rodent carcinogenicity tests probably 
overestimate the risk of estragole carcinogenicity. In fact, the hepatocarcinogenicity of 
estragole in mice has clearly been related to its conversion to 1’-hydroxyestragole, and 
factors infl uencing its formation – or the balance between formation of the active metabolites 
(i.e. 1’-sulfooxyestragole and epoxides) and detoxification by glucuronidation – may also 
cause a related variation in the incidence of tumours (JEURISSEN et al., 2007; SUZUKI et al., 
2012). In male rats, O-demethylation of estragole (leading to detoxifi cation of the compound) 
appears to be a major metabolic route when low doses of estragole are involved, with 
demethylation occurring mainly in lungs and kidneys. Conversely, when rats are exposed to 
high doses of estragole, as a result of saturation of the O-demethylation pathway in lungs and 
kidneys, formation of the proximate carcinogenic metabolite 1’-hydroxyestragole becomes 
relatively more important in liver. The physiologically-based biokinetic (PBBK) model 
predicts that formation of this metabolite in male rats would increase from 16% of the dose 
of 0.07 mg/kg bw to 29% of the dose of 300 mg/kg bw. In contrast, no relative increase in 
formation of 1’-sulfooxyestragole was identifi ed in humans with increasing estragole dose 
levels (RIETJENS et al., 2010). These data point to different metabolic pathways of estragole in 
different species.
Concerning in vitro assays, the literature on genetic toxicology of estragole is scant and 
often with equivocal results. Estragole concentrations of 0.01–1 mM did not induce the 
formation of chromosomal aberrations in the V79 cell line, with and without exogenous 
biotransformation systems (S9) or in primary rat hepatocytes (MULLER et al., 1994). On the 
contrary, an increase in sister chromatid exchange (SCE) and of DNA damage were observed 
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in V79 cells without metabolic activation at high doses (MARTINS et al., 2012). Evidence of 
genotoxicity in in vitro studies comes from the unscheduled DNA synthesis assay in rat 
hepatocytes (CHAN & CALDWELL, 1992; MULLER et al., 1994; NESSLANY et al., 2010).
To the best of our knowledge, there are only two articles dealing with the genotoxicity 
of estragole in human cell lines (ZHOU et al., 2007; VILLARINI et al., 2014). In both studies, the 
cells being used were the human hepatoblastoma HepG2 line, and the estragole concentrations 
being assayed were comparable. ZHOU and co-workers (2007) found an increase in DNA 
adducts at 24 h of incubation. In contrast, our previous study (VILLARINI et al., 2014) showed 
the estragole treatment for 4 h would induce neither cytotoxic effects nor DNA damage or 
apoptosis.
Along this line, we have here observed a very minor and dose-dependent increase in 
MN frequency at 24 h of treatment leading to the conclusion that the genotoxicity of estragole 
is negligible when measured by the CBMN assay. Furthermore, estragole increased the 
percentage of cells in G0/G1 and decreased those in G2/M, indicating an inhibition of HepG2 
cells proliferation via impaired progression of cells from the G1 phase of cell-cycle. Among 
the three principal checkpoints controlling the cell cycle in eukaryotes, G1/S, located at the 
end of the cell cycle’s G1 phase, makes the key decision of whether the cell should divide, 
delay division, or enter a resting stage. The loss of checkpoints provides growth advantages 
to proliferating cancer cells and is thus involved in tumourigenesis and tumour progression 
(PRINDULL, 2008).
3. Conclusions
In summary, the data presented provide novel evidence that estragole does not induce MN 
formation in HepG2 human cells and that it appears to have relatively weak ability to 
modulate cell-cycle. However, because estragole genotoxicity is a complex function based 
on different dose-related mechanisms, further studies are required to further establish the 
safety of estragole in human foods.
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